Sarepta's (SRPT) Clinical Hold Should not Affect Timeline for Development and Approval - Needham & Company Reiterates Buy Rating, $150 PT
Tweet Send to a Friend
Needham & Company analyst Gil Blum reiterated a Buy rating and $150.00 price target on Sarepta Therapeutics (NASDAQ: SRPT), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
